The lungs and soft tissues are the most common secondary sites of renal cell cancer. Patients administered with Afinitor showed 67% progression-free survival compared to placebo.
-
Cross-section of a solid tumour; Afinitor is undergoing clinical trials as a... -
When the tumour is confined to the kidney, renal cell cancer may be... -
The lungs and soft tissues are the most common secondary sites of renal cell...
